OKYO

OKYO Pharma Ltd. (OKYO) | Rumor.io

OKYO Pharma

OKYO

Attention (50-day avg)0%

Attention rank (50-day avg)#4,223

Bullish sentiment (50-day avg)0%

Price to earnings ratio-5.7

Market capitalization71.9M

Earnings per share-0.24

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8.9M

Social

What share of all stock conversation is about OKYO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 8

OKYO Pharma received positive feedback from the FDA, validating the regulatory and clinical path forward for urcosimod and supporting advancement into a global Phase 3 pivotal trial for neuropathic corneal pain.
The FDA has aligned on a single-dose Phase 3 study design and a potential single-trial registration pathway for neuropathic corneal pain, and the new NEPTUNE trial will enroll approximately 111 patients, 2 to 1 randomized.
The NEPTUNE trial is planned to start in the second half of 2026, and OKYO Pharma plans to seek Breakthrough Therapy Designation, though single-trial approval remains conditional on successful results and further FDA review.

Generated by AI

Sentiment

Of the messages about OKYO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.49% +1.12
Bearish	—	—	—	4.51% -1.12

Bullish· Feb 9

The company has a strong setup for Monday, following a strong close.
The asset is undervalued and has a game-changing dry eye disease medication, with a $5.00 forecast.
The public float is 18.42M, with a potential price run to $2.80 if the stock breaks above $2.20.

Bearish· Feb 17

$OKYO has failed to hold the $5 levels, indicating a lack of support for the stock.
The company has zero products, trials, and cash, with the stock being manipulated through a market-making deal to pump the stock for the CEO's benefit.
The stock's parabolic rise is unsustainable, with the RSI over 70, indicating it's getting overbought and likely to correct downward.

Generated by AI

Topics

Of the messages about OKYO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	82.69%
Analysts	—	—	—	9.62%
Controversies	—	—	—	0.64%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	7.05%

Announcements· Oct 5

OKYO Pharma's OK-101 candidate shows safety in mid-stage study for treating dry eye disease.
Around 50 million Americans are affected by dry eye disease, a condition that OKYO Pharma's OK-101 is being developed to treat.
OKYO Pharma announces positive safety data profile for the ongoing OK-101 Phase 2 clinical trial to treat dry eye disease.

Technical Analysis· Feb 17

$OKYO has held the $5 support level again, and could head upwards if volume influx occurs, with $7 as a previous high of day.
The RSI has moved over 70 on $OKYO, indicating the stock may be overbought.
$OKYO has formed a cup pattern, which could be a bullish sign, and may test $6.50 in the coming hour.

Generated by AI

Community

Of the messages about OKYO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	46.19%
Newcomers	—	—	—	53.81%

Regulars· Oct 5

OKYO Pharma Limited traded 395% above average volume, with a 20.09% gain on the day.
OKYO Pharma Limited traded 428% above average volume, with a -12.00% decline on the day.
OKYO Pharma Limited's stock volume was significantly affected by the company's announcement of a partnership with Sustainable Energy Technologies, Inc.

Newcomers· Oct 5

OKYO Pharma Limited's stock is looking strong on the daily chart, with a potential break above $3 and a test of key levels $3 and $3.15.
Newcomers are focusing on the stock's technical analysis, with a key level of $0.1580 - $0.1650 to test and a potential break above $0.15.
The stock has maintained key support levels of $0.12 - $0.1330, and is looking good to continue its upward momentum.

Generated by AI

Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal painLONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in

21d agoYahoo Finance UK

OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference

Detailed price information for Okyo Pharma Limited ADR (OKYO-Q) from The Globe and Mail including charting and trades.

21d agoThe Globe and Mail

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

22d agoYahoo Finance

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary sh

2mo agoYahoo Finance

OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026

Detailed price information for Okyo Pharma Limited ADR (OKYO-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

OKYO Pharma CSO purchases additional shares at $1.49

2mo agoInvesting.com

Also Discussed

Investors talking about OKYO also mention

#	Name	Attention
1	LIPO - Lipella Pharmaceuticals Inc.	——
2	TCBP - TC Biopharm (Holdings) Plc	——
3	Aldeyra Therapeutics, Inc.ALDX	0%+0
4	MGAM - Mobile Global Esports Inc.	——
5	AMAM - Ambrx Biopharma Inc.	——
6	BNOX - Bionomics Limited	——
7	AXLA - Axcella Health Inc.	——
8	Tiziana Life Sciences LtdTLSA	0%0
9	LSDI - Lucy Scientific Discovery Inc.	——
10	Prelude Therapeutics IncorporatedPRLD	0%0

OKYO Pharma Ltd.

Healthcare
Biotechnology

OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases. The company concentrates on ophthalmology and corneal health, with research programs aimed at conditions such as dry eye disease, allergic conjunctivitis, uveitis, and ocular pain. Its pipeline includes urcosimod, an investigational candidate being studied for multiple eye-related indications, and OK-201, another development-stage therapy for ocular pain. OKYO Pharma Ltd. operates as a research and development business in the healthcare sector, targeting unmet needs in diseases affecting the cornea and anterior segment of the eye. Based in London and incorporated in Guernsey, the company plays a specialized role in the biopharmaceutical market by advancing non-opioid and non-steroidal treatment approaches for complex eye disorders.

Website

Location

14/15 Conduit St

London, W1S 2XJ

United Kingdom

Social

What share of all stock conversation is about OKYO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 8

OKYO Pharma received positive feedback from the FDA, validating the regulatory and clinical path forward for urcosimod and supporting advancement into a global Phase 3 pivotal trial for neuropathic corneal pain.
The FDA has aligned on a single-dose Phase 3 study design and a potential single-trial registration pathway for neuropathic corneal pain, and the new NEPTUNE trial will enroll approximately 111 patients, 2 to 1 randomized.
The NEPTUNE trial is planned to start in the second half of 2026, and OKYO Pharma plans to seek Breakthrough Therapy Designation, though single-trial approval remains conditional on successful results and further FDA review.

Generated by AI

Sentiment

Of the messages about OKYO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.49% +1.12
Bearish	—	—	—	4.51% -1.12

Bullish· Feb 9

The company has a strong setup for Monday, following a strong close.
The asset is undervalued and has a game-changing dry eye disease medication, with a $5.00 forecast.
The public float is 18.42M, with a potential price run to $2.80 if the stock breaks above $2.20.

Bearish· Feb 17

$OKYO has failed to hold the $5 levels, indicating a lack of support for the stock.
The company has zero products, trials, and cash, with the stock being manipulated through a market-making deal to pump the stock for the CEO's benefit.
The stock's parabolic rise is unsustainable, with the RSI over 70, indicating it's getting overbought and likely to correct downward.

Generated by AI

Topics

Of the messages about OKYO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	82.69%
Analysts	—	—	—	9.62%
Controversies	—	—	—	0.64%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	7.05%

Announcements· Oct 5

OKYO Pharma's OK-101 candidate shows safety in mid-stage study for treating dry eye disease.
Around 50 million Americans are affected by dry eye disease, a condition that OKYO Pharma's OK-101 is being developed to treat.
OKYO Pharma announces positive safety data profile for the ongoing OK-101 Phase 2 clinical trial to treat dry eye disease.

Technical Analysis· Feb 17

$OKYO has held the $5 support level again, and could head upwards if volume influx occurs, with $7 as a previous high of day.
The RSI has moved over 70 on $OKYO, indicating the stock may be overbought.
$OKYO has formed a cup pattern, which could be a bullish sign, and may test $6.50 in the coming hour.

Generated by AI

Community

Of the messages about OKYO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	46.19%
Newcomers	—	—	—	53.81%

Regulars· Oct 5

OKYO Pharma Limited traded 395% above average volume, with a 20.09% gain on the day.
OKYO Pharma Limited traded 428% above average volume, with a -12.00% decline on the day.
OKYO Pharma Limited's stock volume was significantly affected by the company's announcement of a partnership with Sustainable Energy Technologies, Inc.

Newcomers· Oct 5

OKYO Pharma Limited's stock is looking strong on the daily chart, with a potential break above $3 and a test of key levels $3 and $3.15.
Newcomers are focusing on the stock's technical analysis, with a key level of $0.1580 - $0.1650 to test and a potential break above $0.15.
The stock has maintained key support levels of $0.12 - $0.1330, and is looking good to continue its upward momentum.

Generated by AI

OKYO Pharma

Social

Jul 8

Bullish· Feb 9

Bearish· Feb 17

Announcements· Oct 5

Technical Analysis· Feb 17

Regulars· Oct 5

Newcomers· Oct 5

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026

OKYO Pharma CSO purchases additional shares at $1.49

Also Discussed

OKYO Pharma Ltd.

Company Information

Location

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026

OKYO Pharma CSO purchases additional shares at $1.49

Also Discussed

Social

Jul 8

Bullish· Feb 9

Bearish· Feb 17

Announcements· Oct 5

Technical Analysis· Feb 17

Regulars· Oct 5

Newcomers· Oct 5